Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer - Related Studies

Cisplatin, Etoposide, and Bevacizumab in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer

This study is ongoing, but not recruiting participants.

Study NCT00079040. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Lung Cancer

2	Additional conditions recognized in this trial
		Carcinoma, Small Cell
		Lung Neoplasms

3	More general conditions related to this trial
		Adenocarcinoma
		Carcinoma
		Carcinoma, Neuroendocrine
		Lung Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Germ Cell and Embryonal
		Neoplasms, Glandular and Epithelial
		Neoplasms, Nerve Tissue
		Neuroectodermal Tumors
		Neuroendocrine Tumors
		Respiratory Tract Diseases
		Respiratory Tract Neoplasms
		Thoracic Neoplasms

4	Interventions listed in this trial
		bevacizumab
		cisplatin
		etoposide

5	Additional drug interventions recognized in this trial
		Etoposide phosphate

6	More general drug interventions related to this trial
		Angiogenesis Inhibitors
		Angiogenesis Modulating Agents
		Antineoplastic Agents
		Antineoplastic Agents, Phytogenic
		Growth Inhibitors
		Growth Substances
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		Eastern Cooperative Oncology Group
		National Cancer Institute (NCI)